Can cabozantinib be used for brain transplantation of lung adenocarcinoma?

Cabozantinib, a multitarget tyrosine kinase inhibitor, has shown its therapeutic potential in a variety of solid tumors. Whether cabozantinib is suitable for brain metastases from lung adenocarcinoma has become a matter of great concern.

Cabotinib exerts anti-tumor effects by inhibiting multiple targets related to tumor growth and metastasis, such as MET, VEGFR, RET, etc. This multi-target inhibitory mechanism makes cabozantinib theoretically a therapeutic potential for lung adenocarcinoma brain metastasis because it can simultaneously block multiple signaling pathways that promote tumor growth and spread.

Clinical studies have shown that cabozantinib has shown certain efficacy in a variety of cancers, including lung adenocarcinoma. Especially in patients with RET fusion lung cancer, cabozantinib showed an objective response rate of 28% and a median progression-free survival of 5.5 months. Although these data are not specifically a study of brain metastasis from lung adenocarcinoma, they reflect the effectiveness of cabozantinib in the treatment of lung cancer.

Regarding the efficacy of cabozantinib on brain metastases, some studies have shown that it may have the potential to cross the blood-brain barrier and treat brain metastases. In a retrospective cohort study, cabozantinib demonstrated a high intracranial objective response rate (55%) in patients with progressive intracranial disease who were otherwise treated. This suggests that cabozantinib may have a certain therapeutic effect in patients with brain metastases from lung adenocarcinoma.

When using cabozantinib, you also need to pay attention to its safety and side effects. Common side effects include digestive system effects (such as diarrhea, nausea), hematological effects (such as anemia, thrombocytopenia), and neurological symptoms (such as headache, fatigue). Therefore, when cabozantinib is used to treat brain metastases from lung adenocarcinoma, the patient's response should be closely monitored and the treatment plan adjusted accordingly.